Advanced search
Publication Cover
Integrated Pharmacy Research and Practice Volume 13, 2024 - Issue
Submit an article Journal homepage
13
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Warfarin and Polypharmacy Challenges in Sudan: Drug Interactions in Patient Cohort

Ahmed AA Omer1 Department of Pharmacology Faculty of Pharmacy, University of Gezira, Wad Medani, Gezira State, 21111, SudanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0008-3799-4885
ORCID Icon,
Abdal Mahmoud Elsiddig2 Medani Heart Centre, Wad Medani, Gezira State, 550, Sudan
&
Imad M Taj1 Department of Pharmacology Faculty of Pharmacy, University of Gezira, Wad Medani, Gezira State, 21111, Sudan
Pages 81-89 | Received 29 Feb 2024, Accepted 20 Jun 2024, Published online: 25 Jun 2024

References

  • Lee MTM, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334–338. doi:10.1038/jhg.2013.40
  • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026
  • Wang -Z-Z, Du X, Wang W, et al. Long-term persistence of newly initiated warfarin therapy in Chinese patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2016;9(4):380–387. doi:10.1161/CIRCOUTCOMES.115.002337
  • Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol. 2016;67(16):1941–1955. doi:10.1016/j.jacc.2016.01.072
  • Leite PM, Martins MAP, Das Graças Carvalho M, Castilho RO. Mechanisms and interactions in concomitant use of herbs and warfarin therapy: an updated review. Biomed Pharmacother. 2021;143:112103. doi:10.1016/j.biopha.2021.112103
  • Fung E. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. In: Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers; 2012:893–904.
  • Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacother J Hum Pharmacol Drug Ther. 2004;24(12):1668–1674. doi:10.1592/phco.24.17.1668.52338
  • Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19. doi:10.1136/bmj.329.7456.15
  • Holbrook AM. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106. doi:10.1001/archinte.165.10.1095
  • Medscape, drug interaction checker; 2018. Available from: https://reference.medscape.com/drug-interactionchecker. Accessed: March 15, 2018.
  • Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug‒drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J. 2014;12(1):1–8. doi:10.1186/1477-9560-12-20
  • Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug‒drug and drug-disease interactions. J Manag Care Pharm. 2006;12(8):640–648. doi:10.18553/jmcp.2006.12.8.640
  • Patel PS, Rana DA, Suthar JV, Malhotra SD, Patel VJ. A study of potential adverse drug‒drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. J Basic Clin Pharm. 2014;5(2):44. doi:10.4103/0976-0105.134983
  • Verhovsek M, Motlagh B, Crowther MA, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr. 2008;8(1):1–6. doi:10.1186/1471-2318-8-13
  • Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352–360. doi:10.1161/CIRCULATIONAHA.115.018544
  • Wang M, Zeraatkar D, Obeda M, et al. Drug–drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4051–4100. doi:10.1111/bcp.14833
  • Hylek EM, Chang Y, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000;160(11):1612–1617. doi:10.1001/archinte.160.11.1612
  • Crowther MA. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–1138. doi:10.1056/NEJMoa035241
  • Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. In: Baylor University Medical Center Proceedings. Taylor & Francis; 2001:305–306.
  • You J, Chan F, Wong R, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol. 2005;59(5):582–587. doi:10.1111/j.1365-2125.2005.02361.x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.